SCHEMBL1094584

SCHEMBL1094584

O=S(=O)(c1ccccc1)N(F)c1ncns1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
APOBEC3G Q9HC16 1/20 0.47
ALDH1A1 P00352 4/20 0.40
TDP1 Q9NUW8 2/20 0.38
HSD17B10 Q99714 1/20 0.38
KMT2A Q03164 2/20 0.36
HSD11B1 P28845 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.34
HTR6 P50406 1/20 0.32
NR1I2 O75469 2/20 0.32
SCN9A Q15858 2/20 0.32
PKM P14618 1/20 0.32
SCN5A Q14524 1/20 0.32
GAA P10253 1/20 0.32
RORA P35398 1/20 0.31
RORC P51449 1/20 0.31
RORB Q92753 1/20 0.31
NR1H4 Q96RI1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3478388 0.81 APOBEC3G (0.39) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL14920540 0.81 NR1I2 (0.44) APOBEC3GALDH1A1HSD17B10KMT2AHSD11B1
SCHEMBL1093490 0.77 KDM4E (0.49) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL1094210 0.74 APOBEC3G (0.47) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL3477832 0.73 APOBEC3G (0.46) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL1095059 0.72 APOBEC3G (0.44) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL1094170 0.72 APOBEC3G (0.57) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL1094685 0.71 APOBEC3G (0.47) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL1094212 0.70 APOBEC3G (0.46) APOBEC3GALDH1A1TDP1HSD17B10KMT2A
SCHEMBL141091 0.69 APOBEC3G (0.64) APOBEC3GALDH1A1TDP1HSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8907101-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2014-12-09 US disclosed
US-20130338111-A1 Sulfonamide Derivatives ICAGEN, INC. (US) 2013-12-19 US disclosed
US-20120149679-A1 Sulfonamide Derivatives ICAGEN, INC. 2012-06-14 US disclosed
US-8153814-B2 Sulfonamide derivatives PFIZER LIMITED (GB) 2012-04-10 US disclosed
US-20100197655-A1 SULFONAMIDE DERIVATIVES Pfizer Limited Icagen, Inc. 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197655-A1 SULFONAMIDE DERIVATIVES SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885TDP1 2446/4885
US-20130338111-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885TDP1 2446/4885
US-20120149679-A1 Sulfonamide Derivatives SULT2A1, SULT1A1, TPST2 APOBEC3G 4833/4885ALDH1A1 1369/4885TDP1 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.